(Total Views: 257)
Posted On: 05/29/2020 5:36:48 PM
Post# of 281
NetworkNewsBreaks - Predictive Oncology Inc. (NASDAQ: POAI) Helomics Subsidiary Holds Unique Cancerous Tumor Inventory
Predictive Oncology (NASDAQ: POAI) CEO Dr. Carl Schwartz recently referred to the company’s Helomics subsidiary as a “major asset” during an exclusive NNW interview with Stuart Smith (http://nnw.fm/54qVZ). An article discussing the interview reads, “During the interview, Schwartz pointed out that Helomics’ collection of more than 150,000 cancer tumors is the largest inventory of its kind in the world and that the impressive collection ‘was amassed over the last two decades by physicians sending in cancerous tumors to be tested with the known therapies of the time. The results of these tests were in turn sent back to the referring physicians to be used as a guide or a reference as desired for treatment of the evaluated tumor,’ he continued. ‘And the evaluated tumor was placed back in the physician’s therapy inventory. That’s how we amassed all these tumors.’ . . . Schwartz explained that POAI was intent on proving that it can sequence, ‘which is genetically profile our tumors, and do what is called a ‘reach back,’ or examination of what eventually happened to these patients over an extended period of time. I want to strongly emphasize that Helomics is the only company with the ability to do this ‘reach back’ at this time because only we have a patient history.’”
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
Predictive Oncology (NASDAQ: POAI) CEO Dr. Carl Schwartz recently referred to the company’s Helomics subsidiary as a “major asset” during an exclusive NNW interview with Stuart Smith (http://nnw.fm/54qVZ). An article discussing the interview reads, “During the interview, Schwartz pointed out that Helomics’ collection of more than 150,000 cancer tumors is the largest inventory of its kind in the world and that the impressive collection ‘was amassed over the last two decades by physicians sending in cancerous tumors to be tested with the known therapies of the time. The results of these tests were in turn sent back to the referring physicians to be used as a guide or a reference as desired for treatment of the evaluated tumor,’ he continued. ‘And the evaluated tumor was placed back in the physician’s therapy inventory. That’s how we amassed all these tumors.’ . . . Schwartz explained that POAI was intent on proving that it can sequence, ‘which is genetically profile our tumors, and do what is called a ‘reach back,’ or examination of what eventually happened to these patients over an extended period of time. I want to strongly emphasize that Helomics is the only company with the ability to do this ‘reach back’ at this time because only we have a patient history.’”
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
(0)
(0)
